How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?

被引：0
|
作者：
Michael Drummond
Oriana Ciani
Giulia Fornaro
Claudio Jommi
Eva Susanne Dietrich
Jaime Espin
Jean Mossman
Gerard de Pouvourville
机构：
[1] University of York,Centre for Health Economics
[2] CERGAS,Patient Representative and Visiting Senior Research Associate in the Medical Technology Research Group
[3] SDA Bocconi School of Management,undefined
[4] University of Bonn Pharmaceutical Institute,undefined
[5] Andalusian School of Public Health,undefined
[6] LSE Health,undefined
[7] London School of Economics,undefined
[8] ESSEC,undefined
来源：
BMC Health Services Research | / 23卷
关键词：
Cost-effectiveness analysis; Advanced therapy medicinal products; Health technology assessment; Managed entry agreements; Reimbursement;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Living Health Technology Assessment: Issues, Challenges and Opportunities
    Praveen Thokala
    Tushar Srivastava
    Robert Smith
    Shijie Ren
    Melanie D. Whittington
    Jamie Elvidge
    Ruth Wong
    Lesley Uttley
    PharmacoEconomics, 2023, 41 : 227 - 237
  • [22] Health technology assessment in Germany - Status challenges, and development
    Perleth, M
    Busse, R
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2000, 16 (02) : 412 - 428
  • [23] Living Health Technology Assessment: Issues, Challenges and Opportunities
    Thokala, Praveen
    Srivastava, Tushar
    Smith, Robert
    Ren, Shijie
    Whittington, Melanie D.
    Elvidge, Jamie
    Wong, Ruth
    Uttley, Lesley
    PHARMACOECONOMICS, 2023, 41 (03) : 227 - 237
  • [24] How health technology assessment can help to address challenges in drug repurposing: a conceptual framework
    Abu-Zahra, Teebah
    Grimm, Sabine E.
    Scholte, Mirre
    Raymakers, Adam J. N.
    Kesselheim, Aaron S.
    Joore, Manuela
    DRUG DISCOVERY TODAY, 2024, 26 (06)
  • [25] HOW CAN HEALTH TECHNOLOGY ASSESSMENT HELP IN ADDRESSING DRUG REPURPOSING CHALLENGES? A CONCEPTUAL FRAMEWORK
    Abu-Zahra, T.
    Grimm, S.
    Scholte, M.
    Joore, M.
    VALUE IN HEALTH, 2023, 26 (12) : S354 - S354
  • [26] Regulatory and health technology assessment of cell and gene therapies in Europe: Convergence or divergence?
    Hoogendoorn, Mark
    Fabriek, Babs
    Bloem, Lourens T.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 16 - 16
  • [27] HEALTH TECHNOLOGY ASSESSMENT (HTA) REVIEW OF CELL & GENE THERAPIES: THE ROAD TO REIMBURSEMENT
    Vu, B. K.
    Forsythe, A.
    Nguyen, K.
    Tomaras, D.
    VALUE IN HEALTH, 2020, 23 : S20 - S20
  • [28] Future challenges for health economics and health technology assessment of biological drugs
    László Gulácsi
    The European Journal of Health Economics, 2010, 11 : 235 - 238
  • [29] Health Technology Assessment Challenges in Oncology: 20 Years of Value in Health
    Kim, Hansoo
    Goodall, Stephen
    Liew, Danny
    VALUE IN HEALTH, 2019, 22 (05) : 593 - 600
  • [30] Future challenges for health economics and health technology assessment of biological drugs
    Gulacsi, Laszlo
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2010, 11 (03): : 235 - 238
12345